These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31416753)

  • 1. Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.
    Konishi S; Hatakeyama S; Numakura K; Narita S; Inoue T; Saito M; Tokui N; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Narita S; Kawaguchi T; Habuchi T; Ohyama C
    Clin Genitourin Cancer; 2019 Oct; 17(5):e1080-e1089. PubMed ID: 31416753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
    Numakura K; Kobayashi M; Muto Y; Sekine Y; Takahashi M; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Nanjyo H; Habuchi T
    Sci Rep; 2020 Nov; 10(1):20089. PubMed ID: 33208816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
    Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
    Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
    Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
    Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Wells JC; Stukalin I; Norton C; Srinivas S; Lee JL; Donskov F; Bjarnason GA; Yamamoto H; Beuselinck B; Rini BI; Knox JJ; Agarwal N; Ernst DS; Pal SK; Wood LA; Bamias A; Alva AS; Kanesvaran R; Choueiri TK; Heng DY
    Eur Urol; 2017 Feb; 71(2):204-209. PubMed ID: 27318422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
    Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
    Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma.
    Takahara K; Ando R; Kanao K; Ito T; Miyake H; Sumitomo M; Yasui T; Shiroki R
    Anticancer Res; 2020 Aug; 40(8):4395-4400. PubMed ID: 32727768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy.
    Takamatsu K; Mizuno R; Omura M; Morita S; Matsumoto K; Shinoda K; Kosaka T; Takeda T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
    Clin Genitourin Cancer; 2018 Aug; 16(4):e927-e933. PubMed ID: 29678472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
    Tamura K; Osawa T; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Sugimoto M; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Komiyama M; Tanaka K; Yokomizo A; Kohei N; Shinohara N; Miyake H;
    Jpn J Clin Oncol; 2021 Apr; 51(5):810-818. PubMed ID: 33479762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
    Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.
    Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
    Med Oncol; 2018 Nov; 36(1):6. PubMed ID: 30474747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients.
    Takamatsu K; Mizuno R; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
    Int J Clin Oncol; 2019 Sep; 24(9):1069-1074. PubMed ID: 31065836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
    Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Oya M; Albiges L; Aizawa M; Umeyama Y; Wang J; di Pietro A; Schmidinger M
    ESMO Open; 2023 Dec; 8(6):102034. PubMed ID: 37866029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
    Pérez-Valderrama B; Arranz Arija JA; Rodríguez Sánchez A; Pinto Marín A; Borrega García P; Castellano Gaunas DE; Rubio Romero G; Maximiano Alonso C; Villa Guzmán JC; Puertas Álvarez JL; Chirivella González I; Méndez Vidal MJ; Juan Fita MJ; León-Mateos L; Lázaro Quintela M; García Domínguez R; Jurado García JM; Vélez de Mendizábal E; Lambea Sorrosal JJ; García Carbonero I; González del Alba A; Suárez Rodríguez C; Jiménez Gallego P; Meana García JA; García Marrero RD; Gajate Borau P; Santander Lobera C; Molins Palau C; López Brea M; Fernández Parra EM; Reig Torras O; Basterretxea Badiola L; Vázquez Estévez S; González Larriba JL
    Ann Oncol; 2016 Apr; 27(4):706-11. PubMed ID: 26658889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
    Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
    BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
    Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Tamura K; Komiyama M; Goto T; Yokomizo A; Kohei N; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Iwamoto H; Mitsuzuka K; Morooka D; Shimazui T; Yamamoto Y; Ikeshiro S; Nakagomi H; Morita K; Tomida R; Mochizuki T; Inoue T; Kitamura H; Yamada S; Ito YM; Murai S; Nishiyama H; Shinohara N;
    Cancer Sci; 2020 Jul; 111(7):2460-2471. PubMed ID: 32402135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.